Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $29.03
• Market Cap: $2.31B
• EPS: $-2.92
• 52-Week High: $47.65
• 52-Week Low: $8.69

Market Sentiment

Mineralys Therapeutics, Inc. Common Stock currently has a Neutral sentiment score of 0.09.

About Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, dedicated to developing innovative therapies for hypertension and related cardiovascular conditions. The company boasts a strong pipeline of drug candidates designed to address significant unmet medical needs in the cardiovascular sector. With a strategic focus on advancing patient care and improving treatment outcomes, Mineralys is well-positioned to become a key player in redefi...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Mineralys Therapeutics, Inc. Common Stock and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does MLYS pay dividends?

Mineralys Therapeutics, Inc. Common Stock (MLYS) does not currently pay a regular dividend.

What is MLYS's market cap?

Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market capitalization of $2.31B with a current stock price of $29.03.